Michael Severino, AbbVie vice chairman and president
March 10, 2022 10:18 AM EST
R&D

Look­ing to bat­tle ri­vals in a big mar­ket, Ab­b­Vie is head­ed to the FDA af­ter clear­ing a PhI­II hur­dle for chron­ic mi­graine

John Carroll

Editor & Founder

Ever the ag­gres­sive com­peti­tor, Ab­b­Vie is tak­ing a shot at a sig­nif­i­cant la­bel ex­pan­sion for its mi­graine drug Qulip­ta (ato­gepant) that will give them a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times